Back to Newsroom

Sutro Marks Two Drug Development Milestones

SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first internally-developed antibody drug conjugate, or ADC, using Sutro’s proprietary cell-free protein synthesis technology.  STRO-001 has been manufactured for the planned first quarter 2018 initiation of clinical trials for the treatment of multiple myeloma and aggressive and indolent lymphomas.